Anti-BAFFR antibody therapeutic formulations
US10689451B2 · kind B2 · utility
1Cited by
6References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 15, 2018 |
| Grant date | Jun 23, 2020 |
| Priority date | — |
| Expiry date | May 15, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.